Evidence map›Paper›PMID 38888741›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2025

The effect of incidental dose to pelvic nodes in bladder-only irradiation in the era of IMRT: a dosimetric study.

Gokhan Ozyigit, Alper Kahvecioglu, Mustafa Cengiz, Fazli Yagiz Yedekci, Pervin Hurmuz

Abstract read
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gokhan OzyigitFaculty of Medicine, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey. gozyigit@hacettepe.edu.tr.ORCID 0000-0002-7497-4348
Alper KahveciogluFaculty of Medicine, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey.
Mustafa CengizFaculty of Medicine, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey.
Fazli Yagiz YedekciFaculty of Medicine, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey.
Pervin HurmuzFaculty of Medicine, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWhile three-dimensional radiotherapy (RT) causes high incidental nodal doses in bladder-only irradiation for muscle-invasive bladder cancer (MIBC), the impact on pelvic lymphatics is unclear in the era of intensity-modulated RT (IMRT). This study evaluates incidental doses to pelvic lymphatics in MIBC patients treated with IMRT.

methodsThe data of 40 MIBC patients treated with bladder-only IMRT and concurrent chemotherapy were retrospectively evaluated. The pelvic lymphatics were contoured on initial simulation images and incidental nodal doses were evaluated. The Statistical Package for the Social Sciences (SPSS) version 23.0 (IBM, Armonk, NY, USA) was used for statistics.

resultsMedian RT dose to the bladder was 60 Gy in 30 fractions. In dosimetric analysis, median values of mean dose (D

conclusionThe incidental nodal doses with bladder-only IMRT are heterogeneous and remain below the generally accepted doses for microscopic disease eradication for bladder cancer.

Indexed as

Lymph NodesRadiotherapy, Intensity-ModulatedUrinary Bladder NeoplasmsAdultAgedAged, 80 and overFemaleHumansLymphatic MetastasisMaleMiddle AgedPelvisRadiometryRadiotherapy DosageRetrospective StudiesUrinary BladderBladder preserving therapyChemoradiotherapyElective nodal irradiationRadiotherapyTrimodality treatment

Identifiers

PMID38888741
PMCPMC12014827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.